+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
PARP Inhibitors Drug Therapy Market by Indication, Drug, Line of Therapy, Treatment Setting, End User, Distribution Channel, Therapy Type, Patient Age Group - Global Forecast to 2030- Product Image
PARP Inhibitors Drug Therapy Market by Indication, Drug, Line of Therapy, Treatment Setting, End User, Distribution Channel, Therapy Type, Patient Age Group - Global Forecast to 2030- Product Image
Sale

PARP Inhibitors Drug Therapy Market by Indication, Drug, Line of Therapy, Treatment Setting, End User, Distribution Channel, Therapy Type, Patient Age Group - Global Forecast to 2030

  • PDF Icon

    Report

  • 192 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5674431
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The PARP Inhibitors Drug Therapy Market grew from USD 7.32 billion in 2024 to USD 8.01 billion in 2025. It is expected to continue growing at a CAGR of 9.24%, reaching USD 12.44 billion by 2030.

Unveiling the Role of PARP Inhibitors in Modern Oncology

In recent years, PARP inhibitors have emerged as a transformative class of targeted therapies, fundamentally altering the landscape of oncological treatment. Originally recognized for their efficacy in BRCA-mutated ovarian cancer, these agents have rapidly extended their application into breast, pancreatic, and prostate cancer indications. Their mechanism-disrupting DNA repair pathways in tumor cells-has introduced a novel therapeutic axis that complements existing chemotherapy and immunotherapy regimens. This shift underscores an ongoing evolution toward precision medicine, in which molecular and genetic profiling directly inform treatment selection.

Today’s executive summary offers a concise yet comprehensive overview of the critical developments, market dynamics, and actionable insights relevant to pharmaceutical, biotech, and healthcare stakeholders. By synthesizing the latest clinical advancements, regulatory shifts, competitive strategies, and regional variations, this analysis equips decision-makers with a clear understanding of the PARP inhibitor ecosystem. It also highlights the strategic imperatives necessary to navigate challenges and capitalize on emerging opportunities in this rapidly growing segment of oncology.

Evolving Treatment Paradigms Shaped by Cutting-Edge Innovations

Over the past decade, transformative shifts have redefined PARP inhibitor therapy from a niche intervention to an integral component of advanced cancer care. Landmark regulatory approvals in multiple indications accelerated adoption, while collaborative research uncovered synergistic potentials in combination regimens. The growing emphasis on biomarker-driven patient selection has refined treatment protocols, ensuring that only those most likely to benefit are exposed to potential toxicities.

In parallel, advancements in companion diagnostics have facilitated earlier identification of BRCA-mutated and homologous recombination-deficient tumors, enabling more precise patient stratification. The advent of real-world evidence studies further validated efficacy in broader populations, reinforcing confidence among oncologists and payers. As a result, clinical guidelines have progressively incorporated PARP inhibitors across first-line maintenance and subsequent-line settings, underscoring their enduring impact on therapeutic paradigms.

Navigating US Tariff Revisions: Implications for Access and Cost

The introduction of updated United States tariff structures in 2025 has generated significant headwinds for the importation of patented oncology therapies, including PARP inhibitors. Revised duty rates on key active pharmaceutical ingredients and finished drug forms have raised manufacturing overheads and logistics costs. For domestic producers, these changes have prompted critical reassessments of supply chain configurations, with many exploring near-shoring strategies to mitigate exposure to fluctuating trade barriers.

Concurrently, regulatory bodies and industry associations are engaging in constructive dialogue to alleviate potential access constraints. Temporary duty exemptions for life-saving medications are under consideration, and collaborative initiatives aim to redistribute cost pressures across stakeholders. Despite these efforts, the cumulative impact of new tariffs necessitates adaptive pricing models and reinforced distribution partnerships to maintain patient access without compromising commercial viability.

Decoding Market Segments for Precision Targeting

The PARP inhibitor market is characterized by layered segmentation that underpins targeted go-to-market strategies. Within the broad indication category, breast cancer remains a dominant focus, particularly subpopulations defined by hormone receptor positive and triple-negative profiles. In ovarian cancer, efficacy is tightly correlated to biomarker status, with BRCA-mutated and HRD cohorts showing the most robust responses while Non-HRD patients present ongoing challenges. Pancreatic cancer treatment hinges on disease staging, marked by a clear distinction between early- and advanced-stage applications. Similarly, prostate cancer utilization is influenced by metastatic status, as providers tailor regimens to either localized or disseminated disease.

Drug-specific behaviors further nuance market dynamics as Niraparib, Olaparib, Rucaparib, and Talazoparib each demonstrate distinct pharmacologic profiles, safety considerations, and dosing protocols. Line-of-therapy segmentation reveals growth in maintenance settings following first-line induction, with subsequent-line deployments offering critical salvage options. The setting of care-whether inpatient or outpatient-shapes reimbursement pathways and out-of-pocket burdens for patients. End user categories such as hospitals, retail pharmacies, and specialty clinics delineate distribution strategies, while underlying channels like hospital pharmacies, online dispensaries, and traditional retail pharmacies define logistical frameworks. Finally, the choice between monotherapy and combination therapy regimens and the differential needs of adult versus elderly patient cohorts inform both clinical adoption and commercial outreach.

Regional Market Dynamics Driving Strategic Priorities

Regional dynamics in the Americas illustrate a mature market environment with robust clinical adoption, well-established reimbursement frameworks, and ongoing private-public collaborations that accelerate patient access. In Europe, Middle East & Africa, heterogeneity in regulatory pathways and payer requirements drives variability in rollout timelines and pricing negotiations, necessitating tailored engagement strategies. Across Asia-Pacific, emerging markets present both high growth potential and complex challenges, including diverse healthcare infrastructures, variable regulatory landscapes, and price sensitivity among public payers. Multinational players are increasingly forging partnerships with local distributors and leveraging tiered pricing models to optimize penetration and sustain profitability in these regions.

Competitive Landscape Spotlight on Leading Innovators

The competitive landscape is dominated by four key branded PARP inhibitors, each backed by industry leaders with expansive oncology portfolios and strategic alliances. AstraZeneca’s Olaparib has established a precedent through its first-to-market advantage and extensive indication breadth. GlaxoSmithKline’s Niraparib strengthens its position through aggressive lifecycle management and explorations into combination regimens with immuno-oncology agents. Clovis Oncology’s Rucaparib leverages biomarker-based labeling to concentrate on high-response subgroups, while Pfizer’s Talazoparib differentiates on potency and tolerability profiles. Emerging entrants and innovative partnerships, such as those linking biotech pioneers with established pharmaceutical corporations, are poised to intensify competition through novel mechanisms, next-generation analogs, and targeted delivery platforms.

Strategic Imperatives for Industry Advancements

Industry leaders should prioritize integration of advanced molecular diagnostics into early treatment decision-making workflows to optimize patient selection and improve real-world outcomes. Strengthening collaborations across payer ecosystems and advocacy groups will facilitate development of value-based pricing arrangements that align cost with clinical benefit. Continued investment in combination therapy trials, particularly those pairing PARP inhibitors with immune checkpoint inhibitors or targeted agents, can unlock new therapeutic frontiers and differentiate portfolios. Optimizing manufacturing footprints through regional hubs will mitigate supply chain disruption and tariff exposure. Finally, deploying digital engagement tools targeted to oncologists and patient communities will amplify disease awareness and streamline therapy management.

Rigorous Methodological Framework Underpinning the Analysis

Our analysis draws on a multi-tiered methodology encompassing comprehensive secondary research, primary interviews with leading oncologists and payers, and rigorous data triangulation. Extensive review of peer-reviewed publications, regulatory filings, and clinical trial registries established a solid evidence base. Primary insights were gathered via structured interviews with key opinion leaders, specialty pharmacists, and healthcare administrators to validate market trends, access barriers, and evolving clinical practices. Quantitative data points were cross-verified against proprietary databases and industry consortium reports. Qualitative input from patient advocacy groups provided critical perspectives on care priorities and real-world treatment experiences, ensuring a holistic and balanced view.

Synthesizing Insights for Strategic Clarity

In summary, PARP inhibitors have transitioned from a specialized niche into a cornerstone of precision oncology, driven by clinical innovation, strategic collaborations, and evolving reimbursement paradigms. The intricate segmentation by indication, drug, line of therapy, and care setting highlights multifaceted growth opportunities, while regional market nuances underscore the importance of adaptable strategies. Competitive dynamics remain robust, with established players and emerging innovators vying for differentiation through combination regimens and biomarker-driven approaches. As stakeholders navigate tariff headwinds and access considerations, it is imperative to ground decisions in data-driven insights and sustained engagement with clinical and payer communities.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Indication
    • Breast Cancer
      • Receptor Type
        • Hormone Receptor Positive
        • Triple Negative
    • Ovarian Cancer
      • Biomarker Status
        • Brca Mutated
        • Hrd
        • Non-Hrd
    • Pancreatic Cancer
      • Stage
        • Advanced
        • Early Stage
    • Prostate Cancer
      • Stage
        • Metastatic
        • Non-Metastatic
  • Drug
    • Niraparib
    • Olaparib
    • Rucaparib
    • Talazoparib
  • Line Of Therapy
    • First Line
    • Maintenance
    • Subsequent Line
  • Treatment Setting
    • Inpatient
    • Outpatient
  • End User
    • Hospitals
    • Retail Pharmacies
    • Specialty Clinics
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Therapy Type
    • Combination Therapy
    • Monotherapy
  • Patient Age Group
    • Adults
    • Elderly
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • AstraZeneca plc
  • GlaxoSmithKline plc
  • Clovis Oncology, Inc.
  • Pfizer Inc.
  • Merck & Co., Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. PARP Inhibitors Drug Therapy Market, by Indication
8.1. Introduction
8.2. Breast Cancer
8.2.1. Receptor Type
8.2.1.1. Hormone Receptor Positive
8.2.1.2. Triple Negative
8.3. Ovarian Cancer
8.3.1. Biomarker Status
8.3.1.1. Brca Mutated
8.3.1.2. Hrd
8.3.1.3. Non-Hrd
8.4. Pancreatic Cancer
8.4.1. Stage
8.4.1.1. Advanced
8.4.1.2. Early Stage
8.5. Prostate Cancer
8.5.1. Stage
8.5.1.1. Metastatic
8.5.1.2. Non-Metastatic
9. PARP Inhibitors Drug Therapy Market, by Drug
9.1. Introduction
9.2. Niraparib
9.3. Olaparib
9.4. Rucaparib
9.5. Talazoparib
10. PARP Inhibitors Drug Therapy Market, by Line of Therapy
10.1. Introduction
10.2. First Line
10.3. Maintenance
10.4. Subsequent Line
11. PARP Inhibitors Drug Therapy Market, by Treatment Setting
11.1. Introduction
11.2. Inpatient
11.3. Outpatient
12. PARP Inhibitors Drug Therapy Market, by End User
12.1. Introduction
12.2. Hospitals
12.3. Retail Pharmacies
12.4. Specialty Clinics
13. PARP Inhibitors Drug Therapy Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacies
13.3. Online Pharmacies
13.4. Retail Pharmacies
14. PARP Inhibitors Drug Therapy Market, by Therapy Type
14.1. Introduction
14.2. Combination Therapy
14.3. Monotherapy
15. PARP Inhibitors Drug Therapy Market, by Patient Age Group
15.1. Introduction
15.2. Adults
15.3. Elderly
16. Americas PARP Inhibitors Drug Therapy Market
16.1. Introduction
16.2. United States
16.3. Canada
16.4. Mexico
16.5. Brazil
16.6. Argentina
17. Europe, Middle East & Africa PARP Inhibitors Drug Therapy Market
17.1. Introduction
17.2. United Kingdom
17.3. Germany
17.4. France
17.5. Russia
17.6. Italy
17.7. Spain
17.8. United Arab Emirates
17.9. Saudi Arabia
17.10. South Africa
17.11. Denmark
17.12. Netherlands
17.13. Qatar
17.14. Finland
17.15. Sweden
17.16. Nigeria
17.17. Egypt
17.18. Turkey
17.19. Israel
17.20. Norway
17.21. Poland
17.22. Switzerland
18. Asia-Pacific PARP Inhibitors Drug Therapy Market
18.1. Introduction
18.2. China
18.3. India
18.4. Japan
18.5. Australia
18.6. South Korea
18.7. Indonesia
18.8. Thailand
18.9. Philippines
18.10. Malaysia
18.11. Singapore
18.12. Vietnam
18.13. Taiwan
19. Competitive Landscape
19.1. Market Share Analysis, 2024
19.2. FPNV Positioning Matrix, 2024
19.3. Competitive Analysis
19.3.1. AstraZeneca plc
19.3.2. GlaxoSmithKline plc
19.3.3. Clovis Oncology, Inc.
19.3.4. Pfizer Inc.
19.3.5. Merck & Co., Inc.
20. ResearchAI
21. ResearchStatistics
22. ResearchContacts
23. ResearchArticles
24. Appendix
List of Figures
FIGURE 1. PARP INHIBITORS DRUG THERAPY MARKET MULTI-CURRENCY
FIGURE 2. PARP INHIBITORS DRUG THERAPY MARKET MULTI-LANGUAGE
FIGURE 3. PARP INHIBITORS DRUG THERAPY MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 20. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 22. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 26. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. PARP INHIBITORS DRUG THERAPY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 32. PARP INHIBITORS DRUG THERAPY MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. PARP INHIBITORS DRUG THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TRIPLE NEGATIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BRCA MUTATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HRD, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NON-HRD, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ADVANCED, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY EARLY STAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY METASTATIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NON-METASTATIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NIRAPARIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OLAPARIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RUCAPARIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TALAZOPARIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY MAINTENANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SUBSEQUENT LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INPATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ELDERLY, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 92. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 93. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 94. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2030 (USD MILLION)
TABLE 95. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 96. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2030 (USD MILLION)
TABLE 97. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2030 (USD MILLION)
TABLE 98. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 99. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 100. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 101. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 102. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 103. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 104. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 107. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 108. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 109. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 110. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2030 (USD MILLION)
TABLE 111. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 112. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2030 (USD MILLION)
TABLE 113. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2030 (USD MILLION)
TABLE 114. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 115. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 116. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 117. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 118. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 119. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 120. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 123. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 133. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 140. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 141. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 142. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2030 (USD MILLION)
TABLE 143. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 144. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2030 (USD MILLION)
TABLE 145. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2030 (USD MILLION)
TABLE 146. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 147. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 148. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 149. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 150. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 151. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 152. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 153. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 155. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2030 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 174. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2030 (USD MILLION)
TABLE 176. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 177. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2030 (USD MILLION)
TABLE 178. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2030 (USD MILLION)
TABLE 179. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 180. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 182. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 184. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 186. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 188. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 189. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 190. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 191. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2030 (USD MILLION)
TABLE 192. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 193. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2030 (USD MILLION)
TABLE 194. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2030 (USD MILLION)
TABLE 195. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 196. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 197. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 198. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 199. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 200. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 201. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 202. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 203. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 204. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 205. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 206. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 207. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2030 (USD MILLION)
TABLE 208. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 209. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2030 (USD MILLION)
TABLE 210. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2030 (USD MILLION)
TABLE 211. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 212. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 213. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 214. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 215. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 216. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 217. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 219. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 220. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 221. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 222. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 223. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2030 (USD MILLION)
TABLE 224. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 225. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2030 (USD MILLION)
TABLE 226. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2030 (USD MILLION)
TABLE 227. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 228. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 229. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 230. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 231. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 232. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 233. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 234. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 235. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 236. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 237. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 238. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 239. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2030 (USD MILLION)
TABLE 240. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 241. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2030 (USD MILLION)
TABLE 242. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2030 (USD MILLION)
TABLE 243. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 244. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 245. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 246. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 247. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 248. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 249. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 250. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 251. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 252. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 253. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 254. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 255. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2030 (USD MILLION)
TABLE 256. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 257. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2030 (USD MILLION)
TABLE 258. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2030 (USD MILLION)
TABLE 259. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 260. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 261. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 262. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 263. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 264. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 265. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 266. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 267. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 268. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 269. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 270. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 271. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2030 (USD MILLION)
TABLE 272. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2030 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 278. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 280. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 285. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 286. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 287. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2030 (USD MILLION)
TABLE 288. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 289. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2030 (USD MILLION)
TABLE 290. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2030 (USD MILLION)
TABLE 291. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 292. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 293. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 294. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 295. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 296. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 297. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 298. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 300. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 301. SOUTH AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 302. SOUTH AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 303. SOUTH AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2030 (USD MILLION)
TABLE 304. SOUTH AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 305. SOUTH AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2030 (USD MILLION)
TABLE 306. SOUTH AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2030 (USD MILLION)
TABLE 307. SOUTH AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 308. SOUTH AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 309. SOUTH AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 310. SOUTH AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 311. SOUTH AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THER

Companies Mentioned

The companies profiled in this PARP Inhibitors Drug Therapy market report include:
  • AstraZeneca plc
  • GlaxoSmithKline plc
  • Clovis Oncology, Inc.
  • Pfizer Inc.
  • Merck & Co., Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages192
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 8.01 Billion
Forecasted Market Value ( USD ) by 2030 $ 12.44 Billion
Compound Annual Growth Rate9.2%
Regions CoveredGlobal
No. of Companies Mentioned6

Related Topics

Related Reports

Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Report 2025 - Product Image

Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor - Pipeline Insight, 2025 - Product Image

Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • 120 Pages
  • Global
From
PARP Inhibitor Biomarkers Market by Product, by Service 1 & 2 Testing, by Application, by End-User, and By Region - Product Image

PARP Inhibitor Biomarkers Market by Product, by Service 1 & 2 Testing, by Application, by End-User, and By Region

  • Report
  • 200 Pages
  • Global
From
PARP Inhibitor Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

PARP Inhibitor Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
PARP Inhibitor Biomarkers - Global Strategic Business Report - Product Image

PARP Inhibitor Biomarkers - Global Strategic Business Report

  • Report
  • 278 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.